Systemic Treatment for Noninfectious Intraocular Inflammation

Irfan Khan, Ashvini Reddy, Jennifer E. Thorne

Research output: Contribution to journalReview articlepeer-review


Background: Although uncommon, uveitis and other ocular inflammatory disorders may pose a serious threat to a patient’s vision and quality of life. Purpose: The purpose of this review is to evaluate the indications for immunosuppressive therapy in the treatment of uveitis and to appraise the data regarding their usage, including efficacy and potential side effects. Recent Findings: While some agents such as antimetabolites have been used to treat uveitis for decades, there are now newer medications such as biologics that have recently met with great success. Adalimumab is the first biologic therapy FDA approved for the treatment of uveitis. Summary: There are multiple immunosuppressive therapies available for the treatment of uveitis that allow for sustained control of ocular inflammation and limitation of systemic corticosteroid exposure. Additional research will be necessary to characterize the efficacy of newer agents to determine if they may be superior and tolerated as older therapies.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalCurrent Ophthalmology Reports
Issue number1
StatePublished - Mar 1 2017


  • Biologics
  • Corticosteroids
  • Immunosuppressive drug therapy
  • Ocular inflammatory disease
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Systemic Treatment for Noninfectious Intraocular Inflammation'. Together they form a unique fingerprint.

Cite this